Galux

About Galux

Galux is a company focused on revolutionizing protein therapeutics development through its pioneering AI-driven protein design platform, GaluxDesign. By integrating artificial intelligence and physical principles, Galux aims to bring imagined proteins to life, pushing the limits of drug design and innovation.

Products & Services

GaluxDesign:A proprietary AI platform for protein design, trained on first principles, with modality-agnostic capabilities and high accuracy demonstrated in de novo antibody design.

Specialties

AI-driven protein design De novo antibody design Protein therapeutics Immunogenicity prediction

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 29000000 MR: - FA: $29 million FAN: 29000000	D: 2026-02-09 FD: 2026-02-09	10 investors

Series B Latest

2026-02-09

$29.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Galux Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised